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Background: Both low and high serum phosphate levels may be associated with morbidity and mortality from
cardiovascular disease. As smoking increases risk for type 2 diabetes (as shown by dyslipidemia and hyperglycemia),
we wanted to study whether smoking and type 2 diabetes were associated with serum phosphate and triglyceride
levels independently from other CVD risk factors.
Methods: Upon admittance to the Vindeln Health Education Centre (VHE-centre) for a four-week comprehensive
lifestyle intervention, the participants (1408 women and 1096 men) completed a questionnaire that included their
smoking habits – current smoker or non-smoker. We used multiple linear regression analyses to investigate the
association between smoking and other CVD risk factors with S-P and S-TG levels.
Results: In the non-type 2 diabetes populations, the smokers, compared to the non-smokers, had higher S-P and
higher serum triglycerides (S-TG). In women, serum-TG in smokers with type 2 diabetes was higher than in smokers
with non-type 2 diabetes. Non-type 2 diabetes patients exhibited an inverse relation between S-Glucose (S-Glu) and
S-P and a positive association with S-TG. For men only, an association was seen between age (−) and S-Crea (−)
and S-P. For women only, an association was seen between BMI (−) and S-Cholesterol (+) (S-Chol) and S-P.
Conclusions: Compared to non-smokers, smoking women with non-type 2 diabetes and smoking men with type 2
diabetes had a higher level of S-P and S-TG. The association between smoking and S-P and S-TG levels still existed
after adjusting for age and CVD risk factors in the multiple linear regression analyses.
Trial registration: The study has been registered as a sub-study to the Lifestyle Intervention Trial no.
ISRCTN79355192.
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Optimal serum phosphate (S-P) is an important condi-
tion for effective glucose metabolism. In glucose intoler-
ance, there is a negative association between S-Glucose
(S-Glu) and S-P [1-4]. The low S-P in connection with
obesity indicates an association with biomarkers for
metabolic syndrome and cardiovascular disease (CVD)
risk factors [4-6]; however, high levels of phosphate, al-
though within normal limits, can be an even stronger* Correspondence: lena.haglin@vll.se
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unless otherwise stated.marker for CVD risk with or without renal disease [7-10].
Thus, defining normal S-P levels may be important in un-
derstanding early metabolic disturbances. Reducing high
S-P in patients with Chronic Kidney Disease (CKD) is an
important therapy as well as a possible preventive strategy
in other patients and individuals with high S-P levels [10].
Therefore, phosphate binders could be used in non-
uremic vascular disease to reduce S-P levels [11]. The
CVD risk of high levels of phosphate with respect to CKD
relative to the risk of low S-P due to obesity has been de-
scribed as a double-edge sword [4,8,12]. If this U-shaped
relationship between S-P and CVD risk is true, the pos-
sible links, causes, and mechanisms need more study. De-
fining the level of S-P that influences CVD risk, either lowLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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reference interval in future investigations. As smoking in-
creases risk for type 2 diabetes (as shown by dyslipidemia
and hyperglycemia), we wanted to study whether smoking
and type 2 diabetes were associated with serum triglycer-




The study population included 2504 patients (1408 women
and 1096 men) admitted to the Vindeln Health Education
Centre (VHE-centre) between 1984 and 1996 in groups of
30 for a four-week residential comprehensive treatment.
The patients had a clinical and biochemical assessed diag-
nosis and were referred from primary care and hospitals in
the county (64%, hypertension; 20%, type 2 diabetes; and
55%, BMI >30 (kg/m2). The diagnosis was re-assessed and
confirmed by the physician at the health care centre. In
addition to the main diagnosis, about half of the patients
had a second subsidiary diagnosis, and the prevalence of
multiple risk factors resembling metabolic syndrome
was high. A second subsidiary diagnosis was never type
2 diabetes, chronic kidney disease (CKD), or coronary
heart disease (CHD). At admittance, the participants com-
pleted a lifestyle questionnaire that included questions
about smoking habits – smoker or non-smoker – at time
of admittance. Former smokers were considered non-
smokers. The baseline characteristics for former smokers
and smokers were significantly different in six out of 10
variables, including S-P and S-TG, indicating reversed
level of risk. The personal characteristics of the patient
population, separated into women and men, are described
in Table 1. A recent published study has described theTable 1 Personal characteristics and CVD risk variables in mean
Variable All participants N = 2504 Women
Age, yrs 50.4 (10.1) 50.1
BMI, kg/m2 31.2 (5.4) 31.5
Smokers, % 20.9 1
Type 2 diabetes, % 19.8 1
SBP, mmHg 147 (19) 145
DBP, mmHg 88 (11) 87
S-Glu, mmol/l 6.54 (3.23) 6.33
S-Chol, mmol/l 6.66 (1.41) 6.63
S-TG, mmol/l 2.46 (1.85) 2.18
S-Urate, mmol/l 340 (82) 316
S- Crea, mmol/l 82.4 (15.2) 76.2
S-Ca, mmol/l 2.34 (0.10) 2.35
S-Mg, mmol/l 0.83 (0.13) 0.83
S-P, mmol/l 1.02 (0.21) 1.05
P-value for t-test of mean difference between men and women.lifestyle intervention program used by patients in this
study and the changes in the metabolic profile for the
non-type 2 diabetes and type 2 diabetes patients included
in the present study [13].The life style intervention program
A problem-based learning perspective was established
during the first four weeks, and 114 full-time hours were
dedicated to food preferences, selections, physical exercise,
and stress management. The activities were repeated dur-
ing a four-day revisit to the centre after one or five years to
establish functioning groups as a source to achieve changes
and as a start for individual targets. The main focus was to
combat risk of future cardiovascular disease (CVD). One
outcome was an individual in-home programme. After the
residential period, the patients were expected to practice
their in-home programme in their habitual environment.
During these revisits, the patients and staff revised the in-
home programme according to the patients’ experiences
during the previous year and their health status.
The Ethical Committee of North Sweden at the
University of Umeå (Umeå, Sweden) approved the proto-
col on November 22, 2006 (Dnr 05-177 M).Physical and biochemical variables
On the second day after being admitted to the VHE centre,
systolic blood pressure (SBP; mmHg), body weight (kg),
height (cm), and body mass index (BMI; kg/m2) were re-
corded. For every patient, a trained nurse measured blood
pressure using a semi-automatic machine. Blood was ana-
lysed on the serum sample according to the standard rou-
tines developed at the Department of Clinical Chemistry,
University Hospital, Umeå, Sweden.(sd) for all patients and for women and men separately
N = 1408 Men N = 1096 Women vs. Men P-value
(10.7) 50.8 (9.4) 0.073
(5.7) 30.7 (4.9) 0.000
9.8 22.3 0.136
7.5 22.7 0.000
(19) 148 (19) 0.000
(12) 90 (11) 0.000
(3.02) 6.80 (3.48) 0.000
(1.39) 6.70 (1.44) 0.186
(1.49) 2.81 (2.18) 0.000
(75) 371 (81) 0.000
(12.7) 90.2 (14.5) 0.000
(0.10) 2.34 (0.09) 0.000
(0.13) 0.84 (0.13) 0.019
(0.21) 0.98 (0.20) 0.000
Figure 1 Marginal means of Serum-Phosphate (mmol/l) with
upper and lower confidence limits (95%) for the four groups
and for men and women.
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kinase method (Boehringer Mannheim Diagnostica,
Mannheim, Germany) on either a Hitachi 717 or a
Hitachi 911 analyser. Serum cholesterol (S-Chol) was
determined using an enzymatic method (Boehringer
Mannheim Diagnostica, Mannheim, Germany) on either a
Hitachi 705 or Hitachi 717 analyser. Serum triglycer-
ides (S-TG) were determined using enzymatic methods
(Boehringer Mannheim Diagnostica, Mannheim, Germany)
on a Hitachi 717 analyser. Serum urate (S-Urate) was deter-
mined using an enzymatic Uricase method (Boehringer
Mannheim Diagnostica, Mannheim, Germany) on a Hitachi
705 or Hitachi 717. Serum calcium (S-Ca) was deter-
mined using a complexometric method from Boehringer
Mannheim on SMA II (Technicon) and on a Hitachi
717 analyser (after 1989). Until 1989, serum magnesium
(S-Mg) was determined using the atom absorption tech-
nique; after 1989, serum magnesium was determined using
a colorimetrically-complex method with reagents from
Boehring Mannheim on a Hitachi 717 analyser. Serum
phosphate (S-P) was determined using an ammonium-
molybdate method (Boehringer Mannheim Diagnostica,
Mannheim, Germany) on a Boehringer Mannheim (SMA II
Technicon) and on a Hitachi 717 analyser (after 1989).
Serum creatinin was analysed by Jaffé method with dialysis
on a SMAII (Technicon) before 1989; thereafter and up to
1996, serum creatinin was analysed by an enzymatic creati-
nin PAP (BM) method on a Hitachi 717 analyser (BM).
Statistical analysis
Student’s t-test was used to analyse differences in per-
sonal characteristics and CVD risk variables, and the
Chi-square test was used to analyse differences between
proportions. All p-values were based on two-sided tests.
Interactions with type 2 diabetes were tested using back-
wards elimination and were included if significant. To
study the relationship between CVD risk factors and S-P
and S-TG values, we used multiple linear regression ana-
lyses [14]. The SAS program pack (version 9.3) was used
for the computerized analyses and the SPSS (IBM ver-
sion 20) for data in Figure 1.
Results
Women compared with men
All personal characteristics and CVD risk variables in-
cluded were different for women and men, except for
prevalence of smokers (%), age, and S-Chol (Table 1).
Compared to the men, the women had a higher BMI, S-P,
and S-Ca and a lower SBP, DBP, S-TG, S-Crea, S-Urate,
S-Mg, and S-Glu. The prevalence of type 2 diabetes
was lower for women than for men (Table 1). There-
fore, we stratified for sex in the comparisons between
smokers and non-smokers and non-diabetes and type 2
diabetes patients.Smokers compared with non-smokers
Table 2 (women) and Table 3 (men) provide the meta-
bolic profile in mean (sd) for smokers and non-smokers
for the diagnosis non-type 2 diabetes and type 2 diabetes at
time of admittance. In all four sub-groups, smokers were
younger and had higher S-TG levels than non-smokers.
For non-type 2 diabetes women and men, smoking
was associated with low SBP, DBP, and S-Crea and high
S-P levels and high S-TG (Tables 2 and 3, respectively).
For type 2 diabetes women, smoking was associated with
high S-Glu and high S-Chol (Table 2), whereas smoking
type 2 diabetes men had low S-Urate, high S-Mg and S-P
(Table 3).Smokers compared with smokers
Comparing women who smoke (Table 2, p-value in Col-
umn A and Table 4), high S-TG and high S-Glu in type
2 diabetes (3.55 vs. 2.60 and 12.40 vs. 10.50, respectively)
was not accentuated by smoking when tested in the mul-
tiple linear regression. Smoking induced a higher S-Ca in
women with type 2 diabetes compared to smoking in non-
type 2 diabetes women (2.38 vs. 2.34). This result seems to
be an adverse effect from smoking for type 2 diabetes as
women with type 2 diabetes who were smokers and
women who were non-smokers produced non-significant
differences (Table 2).
Comparing men who smoke, besides the low S-Urate
and higher S-Glu (316 vs. 327 and 11.80 vs. 10.70, respect-
ively) S-TG was further accentuated by smoking confirmed
in the linear regression model (Table 3, p-value in Column
A and Table 4).
Table 2 Mean (sd) for baseline characteristics in women, smokers vs. non-smokers for non-type 2 diabetes and
type 2 diabetes









P-value A Smokers B Non-smokers
Age, yrs 46.1 (11.0) 50.86 (10.1) 0.000 47.6 (11.1) 51.6 (11.7) 0.037 0.4063 0.401
BMI, kg/m2 31.2 (5.8) 31.5 (5.7) 0.515 30.8 (6.5) 32.4 (5.3) 0.083 0.7059 0.030
SBP, mmHg 141 (18.9) 146 (19.0) 0.000 143 (17.0) 146.7 (19.0) 0.198 0.625 0.728
DBP, mmHg 85 (12) 88 (12) 0.001 85 (12) 87 (11) 0.332 0.942 0.254
S-Glu, mmol/l2) 5.45 (1.35) 5.36 (1.07) 0.370 12.40 (5.08) 10.50 (4.40) 0.015 0.000 0.000
S-Chol, mmol/l 6.58 (1.30) 6.65 (1.39) 0.442 7.09 (1.80) 6.48 (1.34) 0.037 0.077 0.100
S-TG, mmol/l 2.22 (1.19) 2.01 (1.14) 0.015 3.55 (2.63) 2.60 (2.40) 0.018 0.002 0.001
S-Urate, mmol/l 316 (72) 320 (74) 0.387 297 (79) 302 (81) 0.727 0.123 0.002
S-Crea, mmol/l 74.4 (11.4) 77.4 (11.7) 0.000 73.5 (24.2) 75.1 (12.8) 0.663 0.891 0.014
S-Ca, mmol/l 2.34 (0.08) 2.35 (0.1) 0.227 2.38 (0.09) 2.36 (0.11) 0.286 0.004 0.080
S-Mg, mmol/l 0.84 (0.12) 0.84 (0.12) 0.854 0.80 (0.11) 0.78 (0.13) 0.191 0.069 0.001
S-P, mmol/l 1.08 (0.20) 1.05 (0.21) 0.032 1.07 (0.16) 1.05 (0.20) 0.577 0.764 0.654
A = comparing smokers with non-type 2 diabetes (n = 234) and smokers with type 2 diabetes (n = 45).
B = comparing non-smokers with non-type 2 diabetes (n = 927) and non-smokers with type 2 diabetes (n = 202).
P-values for t-test of mean differences between smokers and non-smokers and non-diabetes and type 2 diabetes.
Håglin et al. Diabetology & Metabolic Syndrome 2014, 6:39 Page 4 of 7
http://www.dmsjournal.com/content/6/1/39Non-smokers compared with non-smokers
For non-smoking women and men, the difference in S-Mg
between non type 2 diabetes and type 2 diabetes was highly
significant. Thus, smoking may not be involved in low
S-Mg levels in type 2 diabetes. Women with type 2 dia-
betes had higher BMI, S-Glu and S-TG but lower S-Urate,
S-Crea and S-Mg than women with non-type 2 diabetes.
Men with type 2 diabetes had higher S-Glu but lower
S-Urate, S-Crea and S-Mg.Table 3 Mean (sd) for baseline characteristics in men, smoker
type 2 diabetes







Age, yrs 47.5 (8.5) 50.9 (9.5) 0.000 50.8 (9.
BMI, kg/m2 30.5 (4.6) 30.9 (5.0) 0.298 29.4 (4.
SBP, mmHg 143 (18) 150 (19) 0.000 144 (18
DBP, mmHg 87 (11) 91 (11) 0.000 88 (11
S-Glu, mmol/l2) 5.64 (1.64) 5.57 (1.40) 0.582 11.80 (5
S-Chol, mmol/l 6.76 (1.54) 6.71 (1.37) 0.691 6.78 (1.4
S-TG, mmol/l 3.17 (2.54) 2.61 (1.99) 0.006 3.65 (3.0
S-Urate, mmol/l 376 (79) 388 (73) 0.044 316 (91
S-Crea, mmol/l 86.5 (12.5) 91.5 (13.4) 0.000 85.4 (17
S-Ca, mmol/l 2.34 (0.09) 2.33 (0.09) 0.565 2.33 (0.0
S-Mg, mmol/l 0.85 (0.16) 0.84 (0.13) 0.644 0.85 (0.1
S-P, mmol/l 1.01 (0.21) 0.97 (0.21) 0.022 1.02 (0.1
A = comparing smokers with non- type 2 diabetes (n = 185) and smokers with type
B = comparing non smokers with non- type 2 diabetes (n = 662) and non smokers w
P-values for t-test of mean differences between smokers and non-smokers and nonMultiple linear regression with S-P as the dependent variable
The level of S-P constitutes the dependent variable in the
multiple linear regression analysis and most common risk
factors for CVD were included as confounding independ-
ent variables in the test of association between smoking
and type 2 diabetes and the level of S-P (Table 5). Type 2
diabetes diagnosis interacted with S-Glu in both women
and men and with S-Chol in women only, so it was in-




P-value A Smokers B Non-smokers
8) 53.5 (8.9) 0.044 0.012 0.001
8) 30.8 (4.9) 0.057 0.119 0.735
) 149 (19) 0.072 0.819 0.603
) 89 (11) 0.324 0.611 0.066
.4) 10.70 (4.66) 0.128 0.000 0.000
9) 6.59 (1.59) 0.436 0.949 0.355
2) 2.91 (2.00) 0.031 0.230 0.062
) 327 (83) 0.393 0.000 0.000
.9) 89.0 (16.6) 0.154 0.603 0.050
9) 2.34 (0.12) 0.390 0.717 0.214
3) 0.81 (0.11) 0.020 0.915 0.001
9) 0.97 (0.16) 0.045 0.694 0.966
2 diabetes (n = 59).
ith type 2 diabetes (n = 190).
-diabetes and type 2 diabetes.
Table 4 Multiple linear regression analysis with S-TG values
as the dependent variable (Standardized parameter
estimates and p-value and R2)
Women N = 1408 Men N = 1096
Variable Par est p-value Par est p-value
Age, yr. −0.012 0.655 −0.013 0.642
BMI, kg/m2 0.032 0.185 0.113 0.000
Smoking 0.069 0.003 0.108 0.000
SBP, mmHg 0.009 0.702 −0.032 0.250
S-Glu, mmol/l 0.317 0.000 0.264 0.000
S-Chol, mmol/l 0.288 0.000 0.441 0.000
S-Urate, mmol/l 0.189 0.000 0.133 0.000
S-Crea, mmol/l −0.034 0.148 −0.015 0.610
S-Ca, mmol/l 0.034 0.156 0.001 0.975
S-Mg, mmol/l −0.060 0.012 −0.073 0.008
S-P, mmol/l −0.002 0.941 0.021 0.441
Type 2 diabetes −0.483 0.000 0.267 0.047
Type 2 diabetes *S-Glu −0.285 0.017 −0.184 0.135
Type 2 diabetes *S-Chol 0.733 0.000 −0.162 0.180
R2 29.4% 25,2%
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interaction between type 2 diabetes and S-Glu (+) was
significantly associated with the S-P levels in both women
and men. The inverse relationship between S-Glu and S-P
existed only for non-type 2 diabetes patients (i.e., the
higher S-Glu, the lower S-P levels). The multiple linearTable 5 Multiple linear regression analysis with S-P values
as the dependent variable (Standardized parameter
estimates and p-value and R2)
Women N = 1408 Men N = 1096
Variable Par est p-value Par est p-value
Age, yr. −0.017 0.569 −0.137 0.000
BMI, kg/m2 −0.156 0.000 −0.049 0.123
Smoking 0.053 0.047 0.064 0.032
SBP, mmHg −0.030 0.278 −0.045 0.132
S-Glu, mmol/l −0.209 0.008 −0.249 0.002
S-Chol, mmol/l 0.088 0.005 −0.007 0.859
S-TG, mmol/l −0.002 0.941 0.026 0.441
S-Urate, mmol/l 0.098 0.001 0.051 0.130
S-Crea, mmol/l 0.017 0.540 0.061 0.049
S-Ca, mmol/l 0.091 0.001 0.182 0.000
S-Mg, mmol/l 0.169 0.000 0.168 0.000
Type 2 diabetes 0.158 0.251 0.027 0.854
Type 2 diabetes *S-Glu 0.375 0.006 0.293 0.029
Type 2 diabetes *S-Chol −0.312 0.013 −0.084 0.525
R2 8.7% 11.0%regression analysis also revealed that women with type 2
diabetes had higher S-P the lower their S-Chol level, and
non- type 2 diabetes women had higher S-P the higher
their S-Chol level. For men but not for women, an asso-
ciation was seen for age (−) and S-Crea (+) with the
level of S-P.
Multiple linear regression with S-TG as the
dependent variable
The level of S-TG constitutes the dependent variable in
the multiple linear regression analysis and most com-
mon risk factors for CVD were included as confounding
independent variables in the test of association between
smoking and type 2 diabetes and the level of S-TG
(Table 4). Associations between smoking (+), B-Glu (+),
S-Chol (+), S-Urate (+), and S-Mg (−) and S-TG were
shown for both women and men. In women only, type 2
diabetes (−) and its interaction with both glucose (−)
and cholesterol (+) were strong and significantly associ-
ated with S-TG (Table 4). In men only, type 2 diabetes
(+) and BMI (+) were associated with S-TG (Table 4).
Discussion
We found a higher level of S-P and S-TG in smokers
compared to non-smokers in non- type 2 diabetes
women and men. These associations still existed after
adjusting for age and CVD risk factors in the multiple
linear regression analysis. No interaction between smok-
ing and type 2 diabetes in the association with S-P levels
was revealed while interaction between S-Glu and type 2
diabetes was positively associated with S-P. This indi-
cates an existence of high but normal S-P levels in type
2 diabetes as well (Figure 1). The adverse and combined
association between CVD risk with smoking in type 2
diabetes may partly be due to high S-P levels in addition
to a high S-TG levels.
An inverse relationship between S-Glu and S-P in
non-type 2 diabetes women and men, between age and
S-P in men, and BMI and S-P in women indicate the
need to adjust for sex, age, and BMI in the assessment
of CVD risk factors associated with S-P levels. Age-
related differences in S-P between women and men may
be due to differences in renal thresholds for phosphate
[15]. The comparison of smokers with non-smokers
after stratification for sex reveals higher S-P as well as
higher S-TG levels and a lower SBP and DBP in both
women and men. In a community study, a higher preva-
lence of smokers was seen in the highest quartile of
serum phosphate [9]. Some studies have reported higher
but within normal levels of S-P for smokers without a
discussion of the importance of S-P with respect to either
CVD risk or insulin resistance for smokers [9,16]. The
present study highlights associations between some con-
ventional CVD-risk factors and high but normal S-P levels
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pattern related to CVD risk, not including patients with
kidney disease and hyperphosphatemia. In chronic kidney
disease, a pathological level of S-P (hyperphosphatemia) is
frequently reported as S-P may interact with calcium,
which increases CVD risk [8].
Increased levels of S-TG and S-P in smokers and type
2 diabetes patients compared with non-smokers and
non-type 2 diabetes patients indicate a common disturb-
ance of metabolism linked to CVD risk associated with
insulin resistance. A high level of glycosylated haemoglo-
bin (HbA1c) in smokers may be an indicator for insulin
resistance, but the mechanism behind this is still unclear
[17]. In an earlier study, S-P was shown to be a marker
for glycaemia control [18].
In light of this study, future research should address
the following question: Does the high normal level of S-P
signal insulin resistance in smokers and in patients with
type 2 diabetes? Factors contributing to a high level of S-P
in smokers are largely unknown and sources and mecha-
nisms responsible for an increase in S-P in smokers and
the association between level of S-Glu and level of S-P in
type 2 diabetes needs further investigation.
There are three possible mechanisms or explanations
for a high level of S-P that may be present in smokers and
in patients with type 2 diabetes: 1) an increased threshold
for reabsorption of phosphate in the kidney tubules can
partly be explained by a decrease in the level of parathy-
roid hormone (PTH) [15,19]; 2) low bone mineral content
(BMC) analysis has shown that smokers have greater bone
loss than non-smokers perhaps as a result of mobilization
of phosphate from bone by either increased resorption or
decreased mineralisation revealed [20]; and 3) a decreased
cellular uptake of glucose for intracellular energy metabol-
ism (i.e., phosphorylation) may be related to both low oxy-
gen consumption and the level of S-P, described as affinity
hypoxia [3].
We believe that the higher S-P may be associated with
intracellular depletion of Pi, oxygen, and glucose. A dis-
turbed oxidative phosphorylation may explain lower
ATP production in offspring who have parents with type
2 diabetes [21] and this may also explain why recovery
from exercise in smokers involves a delay in adenosine
triphosphate (ATP) resynthesis [22]. Intracellular phos-
phate depletion may also underlie hyperinsulinemia [23].
The important findings that type 2 diabetes was associ-
ated with S-TG – although in opposite directions in
women (−) and men (+) and stronger for women than men
(p = 0.000 vs. p = 0.047) – may be associated with the level
of other risk factors in the model and, for women, associ-
ated with the level of S-Cholesterol. In women only, the
interaction between type 2 diabetes and cholesterol and
S-TG could explain the opposite directions of associa-
tions. Smoking was strongly associated with S-TG aftercontrol for the other CVD risk factors resembling meta-
bolic syndrome.
Another important finding that links these two condi-
tions (metabolic disturbance in smokers and in type 2
diabetes) to insulin resistance and CVD risk is dyslipid-
emia (i.e., high S-TG). We found that high S-TG in type
2 diabetes men but not women was further accentuated by
smoking (i.e., higher S-TG in smokers vs. non-smokers).
Smokers had higher visceral obesity as shown by a high
waist/hip ratio [24]. Thus smoking is associated with dys-
lipidemia and central fat accumulation [25]. A study on
men with and without cardiovascular disease found that
S-TG levels were higher in smokers than non-smokers
[26]. Smoking and very high levels of TG were associ-
ated with myocardial infarction in women with diabetes
mellitus [27]. The higher S-TG might indicate (in addition
to an increase in S-Glu) that insulin dependent glucose
transport is affected and the increased risk of metabolic
syndrome with smoking may be associated with high
S-TG but not linked to insulin resistance [28]. The
higher S-TG in smokers indicates a disturbed metabolism
of fat (i.e., disturbed β-oxidation). In addition, the lack of
oxygen entering a cell (affinity hypoxia) may negatively
affect glucose transport and oxidative phosphorylation [12],
eventually contributing to reduced combustion of fat. Noc-
turnal intermittent hypoxia was associated with increased
risk of developing type 2 diabetes, a finding that supports
the present hypothesis [29].
The weakness of this study was the cross-sectional de-
sign – descriptive data from a non-randomly selected
population. Another limitation was the lack of adjust-
ments of alcohol consumption and social differences. In
addition, we had no access to information regarding in-
sulin levels or measures for insulin resistance.
Conclusion
This study reveals that smoking is associated with higher
although within normal limits of S-P levels and that S-Glu
is negatively associated with S-P in non-type 2 diabetes
patients, indicating glucose intolerance. Increased levels of
S-TG and S-P in smokers and type 2 diabetes patients
compared with non-smokers and non-type 2 diabetes pa-
tients indicate a common disturbance of metabolism
linked to CVD risk associated with insulin resistance. Fu-
ture studies on the causal relation between cigarette
smoking and risk for insulin resistance should address S-P
levels and include the possible effects of smoking cessa-
tion on reducing S-P and S-TG levels.
In every study of metabolic syndrome and obesity in
relation to CVD risk, associations and influences from
smoking need to be considered as smoking independ-
ently contributes to both high S-TG and high S-P levels.
Although the smoking-S-TG association was stronger than
what was found for S-P, this result provides information
Håglin et al. Diabetology & Metabolic Syndrome 2014, 6:39 Page 7 of 7
http://www.dmsjournal.com/content/6/1/39for future studies on CVD risk and high S-P levels in gen-
eral. As our study shows, smoking needs to be considered
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